Table 1.
Dose Level (Cohort) | ABT-751 mg BID (not mg/m2) | Carboplatin AUC | Planned enrollment | Enrolled patients |
---|---|---|---|---|
1 | 100 | 4.5 | 1–6 | 1 |
2 | 125 | 4.5 | 1–6 | 1 |
3## | 125 | 6 | 1–6 | 5 |
4 | 150 | 6 | 3–6 | 5 |
5 | 175 | 6 | 3–6 | 0 |
6 | 200 | 6 | 3–6 | 0 |
Expansion cohort | MTD | MTD | 10 | 7 |
After dose-limiting toxicities (DLTs) were identified at dose level 4, additional 4 patients were enrolled at the level 3 dose (patients 10, 11, 12, 13).